Resolutions from the Annual General Meeting of Novo Nordisk A/S

Bagsværd, Denmark, 24 March 2022 – Now, Novo Nordisk A/S held its Yearly General Assembly.

At the Once-a-year General Meeting, Helge Lund, chair of the Board of Administrators communicated: “Novo Nordisk designed fantastic development in the previous year and exceeded anticipations with strong monetary functionality. We broadened our technological innovation platforms and product pipeline to fortify the basis for lengthy-expression development, whilst investing substantially in growing our long term generation potential. Our extended-standing aspiration of developing price for culture is more applicable than ever, and we carry on to provide more clients in have to have all-around the environment in line with our intent of driving adjust in diabetes and other major long-term ailment.”

Resolutions adopted at the Once-a-year General Meeting
Economical 12 months 2021 and board remuneration

The last dividend for 2021 of DKK 6.90 for every single Novo Nordisk A or B share of DKK .20. The full dividend for 2021 of DKK 10.40 consists of both equally the interim dividend of DKK 3.50 for each individual Novo Nordisk A and B share of DKK .20 which was paid out in August 2021 and the closing dividend of DKK 6.90 for just about every Novo Nordisk A and B share of DKK .20 to be paid out in March 2022. T
The precise remuneration of the Board of Directors for 2021 and the remuneration level for 2022 ended up permitted.
The Remuneration Report 2021 was permitted (advisory vote).

Elections

Re-election of Helge Lund as chair of the Board of Administrators.
Election of Henrik Poulsen as vice chair of the Board of Directors.
Re-election of Jeppe Christiansen, Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Kasim Kutay and Martin Mackay as members of the Board of Administrators.
Election of Christina Law as new member of the Board of Administrators.
Re-appointment of Deloitte Statsautoriseret Revisionspartnerselskab as the Company’s auditor.

Shares and cash

Reduction of the Company’s B share capital by cancellation of element of the Company’s personal holding of B shares. The Company’s B share funds is decreased by DKK 6,000,000 from DKK 354,512,800 to DKK 348,512,800. The Company’s A share cash of DKK 107,487,200 continues to be unchanged, whereby the Company’s share funds will volume to DKK 456,000,000.
Authorisation to the Board of Directors right up until the Once-a-year Normal Assembly 2023 to enable the Enterprise to repurchase own shares of up to 10% of the share capital matter to a keeping restrict of 10% of the share money.
Extension of the authorisation to the Board of Directors to enhance the Firm’s share money for a time period of one particular yr till 24 March 2024 up to nominally DKK 45,600,000.

Other

Amendments to the Remuneration Policy relating to payment of contribution to social security taxes imposed by foreign authorities exterior the EU and concerning severance payment.
Modification to the Articles of Affiliation about elimination of age restrict on candidates standing for election to the Board of Administrators.

The meeting was held as a partially electronic meeting enabling shareholders to participate either in individual or pretty much. The shareholders experienced been encouraged to physical exercise their rights by distributing proxies or votes by correspondence in progress of the Once-a-year Standard Meeting.

Composition of the Board of Administrators and its committees
In February 2022, Novo Nordisk workforce in Denmark elected four board members, Elisabeth Dahl Christensen, Liselotte Hyveled, Mette Bøjer Jensen and Thomas Rantzau for a time period of four years adhering to the Annual Basic Meeting 2022.

Following the Once-a-year Typical Assembly, the Board of Directors held a board assembly to appoint members of its committees.

The Board of Administrators, like its committees, is now composed as follows:

Helge Lund (chair of the Board and chair of the Nomination Committee)
Henrik Poulsen (vice chair of the Board, member of the Audit Committee and the Remuneration Committee)
Elisabeth Dahl Christensen (worker representative and member of the Remuneration Committee)
Jeppe Christiansen (chair of the Remuneration Committee)
Laurence Debroux (chair of the Audit Committee and member of the Remuneration Committee)
Andreas Fibig (member of the Research & Development Committee)
Sylvie Grégoire (member of the Audit Committee, the Nomination Committee and the Study & Development Committee)
Liselotte Hyveled (staff representative and member of the Investigation & Improvement Committee)
Mette Bøjer Jensen (employee representative and member of the Audit Committee)
Kasim Kutay (member of the Nomination Committee and the Study & Progress Committee)
Christina Law (member of the Audit Committee)
Martin Mackay (chair of the Study & Enhancement Committee and member of the Remuneration Committee)
Thomas Rantzau (staff representative and member of the Nomination Committee)

Novo Nordisk is a main worldwide healthcare firm, founded in 1923 and headquartered in Denmark. Our purpose is to drive modify to defeat diabetic issues and other significant chronic disorders these types of as obesity and uncommon blood and endocrine disorders. We do so by groundbreaking scientific breakthroughs, increasing entry to our medicines and functioning to protect against and eventually heal disease. Novo Nordisk employs about 47,800 people in 80 nations around the world and marketplaces its items in about 170 nations. Novo Nordisk’s B shares are shown on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Trade (NVO). For more details, pay a visit to novonordisk.com, Fb, Twitter, LinkedIn, YouTube.